Blood

Burkitt lymphoma

ORPHA:543 ↗Gene MYC

Search all Burkitt lymphoma trialsAlert me when a trial opens

111

studies recruiting now

as of 7 Sept 2026

973

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

6 May 2026

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 2NCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor National Cancer Institute (NCI)Where United States, Australia, Canada +1 (156 sites)Studying Biospecimen Collection, BlinatumomabUpdated 4 Sept 2026

See details

RecruitingPhase 2 / Phase 3NCT07570173

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Sponsor Merck Sharp & Dohme LLCWhere Denmark, Greece, Israel +5 (21 sites)Studying MK-1045, BlinatumomabUpdated 3 Sept 2026

See details

RecruitingPhase 1 / Phase 2NCT06395103

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Sponsor Merck Sharp & Dohme LLCWhere United States, Australia, Belgium +20 (71 sites)Studying Zilovertamab vedotinUpdated 3 Sept 2026

See details

RecruitingPhase 2NCT03739814

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Sponsor National Cancer Institute (NCI)Where United States, Puerto Rico (277 sites)Studying Biospecimen Collection, BlinatumomabUpdated 2 Sept 2026

See details

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor Alliance for Clinical Trials in OncologyWhere United States, Canada (460 sites)Studying Allopurinol, CytarabineUpdated 2 Sept 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 111 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Australia Belgium Brazil Canada Chile Colombia Czechia Denmark France Germany Greece Hungary Israel Italy Japan Netherlands Puerto Rico Slovakia South Korea Spain Sweden Taiwan Turkey (Türkiye)United Kingdom United States

Keep watching

Get an email when a new Burkitt lymphoma study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:543 ↗

About Burkitt lymphoma

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (MYC).

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Phase 3Rituximab (Blitzima)

Phase 2Ixabepilone (Ixempra kit)

Phase 1Alisertib

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).